KR20110057188A - 바이오마커 프로파일 측정 시스템 및 방법 - Google Patents
바이오마커 프로파일 측정 시스템 및 방법 Download PDFInfo
- Publication number
- KR20110057188A KR20110057188A KR1020117007024A KR20117007024A KR20110057188A KR 20110057188 A KR20110057188 A KR 20110057188A KR 1020117007024 A KR1020117007024 A KR 1020117007024A KR 20117007024 A KR20117007024 A KR 20117007024A KR 20110057188 A KR20110057188 A KR 20110057188A
- Authority
- KR
- South Korea
- Prior art keywords
- biomarkers
- biomarker
- subject
- affective disorder
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 233
- 239000000090 biomarker Substances 0.000 title claims description 417
- 238000005259 measurement Methods 0.000 title description 21
- 208000019022 Mood disease Diseases 0.000 claims abstract description 146
- 208000017194 Affective disease Diseases 0.000 claims abstract description 109
- 108020004414 DNA Proteins 0.000 claims description 162
- 238000004422 calculation algorithm Methods 0.000 claims description 113
- 238000012360 testing method Methods 0.000 claims description 94
- 238000004458 analytical method Methods 0.000 claims description 84
- 210000004369 blood Anatomy 0.000 claims description 72
- 239000008280 blood Substances 0.000 claims description 72
- 239000012472 biological sample Substances 0.000 claims description 69
- 239000002299 complementary DNA Substances 0.000 claims description 66
- 150000007523 nucleic acids Chemical class 0.000 claims description 66
- 238000002493 microarray Methods 0.000 claims description 57
- 108020004707 nucleic acids Proteins 0.000 claims description 57
- 102000039446 nucleic acids Human genes 0.000 claims description 57
- 108010032969 beta-Arrestin 1 Proteins 0.000 claims description 44
- 208000024891 symptom Diseases 0.000 claims description 44
- 238000007405 data analysis Methods 0.000 claims description 39
- 238000012706 support-vector machine Methods 0.000 claims description 39
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 36
- 238000003066 decision tree Methods 0.000 claims description 36
- 208000020925 Bipolar disease Diseases 0.000 claims description 32
- 238000013528 artificial neural network Methods 0.000 claims description 30
- 208000030963 borderline personality disease Diseases 0.000 claims description 29
- 102100037602 P2X purinoceptor 7 Human genes 0.000 claims description 25
- 101710189965 P2X purinoceptor 7 Proteins 0.000 claims description 25
- 238000003745 diagnosis Methods 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 24
- 238000003860 storage Methods 0.000 claims description 23
- 102100021079 Ornithine decarboxylase Human genes 0.000 claims description 21
- 238000004590 computer program Methods 0.000 claims description 20
- 230000003001 depressive effect Effects 0.000 claims description 18
- 230000002068 genetic effect Effects 0.000 claims description 15
- 238000011156 evaluation Methods 0.000 claims description 14
- 208000020401 Depressive disease Diseases 0.000 claims description 12
- 230000007246 mechanism Effects 0.000 claims description 10
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 208000025748 atypical depressive disease Diseases 0.000 claims description 6
- 108700012928 MAPK14 Proteins 0.000 claims description 5
- 238000000513 principal component analysis Methods 0.000 claims description 3
- 102000007378 beta-Arrestin 1 Human genes 0.000 claims 3
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 claims 2
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 claims 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims 2
- 101150003941 Mapk14 gene Proteins 0.000 claims 2
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 claims 2
- 101000585693 Homo sapiens Mitochondrial 2-oxodicarboxylate carrier Proteins 0.000 claims 1
- 101001041245 Homo sapiens Ornithine decarboxylase Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 306
- 238000013518 transcription Methods 0.000 description 142
- 230000035897 transcription Effects 0.000 description 142
- 241000282414 Homo sapiens Species 0.000 description 140
- 239000000523 sample Substances 0.000 description 117
- 238000012549 training Methods 0.000 description 100
- 230000014509 gene expression Effects 0.000 description 83
- 208000028173 post-traumatic stress disease Diseases 0.000 description 55
- 230000002103 transcriptional effect Effects 0.000 description 55
- 102000004169 proteins and genes Human genes 0.000 description 44
- 238000007635 classification algorithm Methods 0.000 description 43
- 102100029649 Beta-arrestin-1 Human genes 0.000 description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 41
- 230000000994 depressogenic effect Effects 0.000 description 37
- 239000003814 drug Substances 0.000 description 31
- 229940079593 drug Drugs 0.000 description 30
- 238000003752 polymerase chain reaction Methods 0.000 description 30
- 238000007637 random forest analysis Methods 0.000 description 30
- 201000010099 disease Diseases 0.000 description 24
- 238000003753 real-time PCR Methods 0.000 description 24
- 230000001154 acute effect Effects 0.000 description 22
- 239000012634 fragment Substances 0.000 description 22
- 102100031269 Putative peripheral benzodiazepine receptor-related protein Human genes 0.000 description 21
- 101710166801 Translocator protein Proteins 0.000 description 21
- 208000024714 major depressive disease Diseases 0.000 description 21
- 101710120430 Ornithine decarboxylase 1 Proteins 0.000 description 20
- 102000007379 beta-Arrestin 2 Human genes 0.000 description 20
- 108010032967 beta-Arrestin 2 Proteins 0.000 description 20
- 230000000875 corresponding effect Effects 0.000 description 20
- 238000009396 hybridization Methods 0.000 description 20
- 239000013615 primer Substances 0.000 description 20
- 108090001005 Interleukin-6 Proteins 0.000 description 19
- 102100021258 Regulator of G-protein signaling 2 Human genes 0.000 description 18
- 101710140412 Regulator of G-protein signaling 2 Proteins 0.000 description 18
- 238000002790 cross-validation Methods 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 238000012545 processing Methods 0.000 description 16
- 102100026359 Cyclic AMP-responsive element-binding protein 1 Human genes 0.000 description 15
- 101000855516 Homo sapiens Cyclic AMP-responsive element-binding protein 1 Proteins 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 15
- 208000014674 injury Diseases 0.000 description 15
- 238000013459 approach Methods 0.000 description 14
- 238000012216 screening Methods 0.000 description 14
- 230000008733 trauma Effects 0.000 description 14
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 13
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 13
- 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 description 13
- 102100037838 Prolyl endopeptidase Human genes 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000010839 reverse transcription Methods 0.000 description 13
- 101150117962 DUSP1 gene Proteins 0.000 description 12
- 102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 description 12
- 101150012093 MKP1 gene Proteins 0.000 description 12
- 101100478343 Schizosaccharomyces pombe (strain 972 / ATCC 24843) srk1 gene Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 102100029796 Protein S100-A10 Human genes 0.000 description 11
- 108010015695 S100 calcium binding protein A10 Proteins 0.000 description 11
- 238000003491 array Methods 0.000 description 11
- -1 for example Substances 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 208000020016 psychiatric disease Diseases 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 201000009032 substance abuse Diseases 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 10
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 description 10
- 101710114597 Sodium-dependent serotonin transporter Proteins 0.000 description 10
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 102100036664 Adenosine deaminase Human genes 0.000 description 9
- 208000019901 Anxiety disease Diseases 0.000 description 9
- 101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 description 9
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 9
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 9
- 238000004364 calculation method Methods 0.000 description 9
- 238000003046 intermediate neglect of differential overlap Methods 0.000 description 9
- 238000007477 logistic regression Methods 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 238000010200 validation analysis Methods 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000012795 verification Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 238000010801 machine learning Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 238000003499 nucleic acid array Methods 0.000 description 6
- 230000001003 psychopharmacologic effect Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 238000000018 DNA microarray Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 210000003567 ascitic fluid Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000003722 extracellular fluid Anatomy 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000013138 pruning Methods 0.000 description 5
- 208000011117 substance-related disease Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010010144 Completed suicide Diseases 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 102000034286 G proteins Human genes 0.000 description 4
- 108091006027 G proteins Proteins 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 208000028683 bipolar I disease Diseases 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 229940127234 oral contraceptive Drugs 0.000 description 4
- 239000003539 oral contraceptive agent Substances 0.000 description 4
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 4
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- 206010013654 Drug abuse Diseases 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- 206010037180 Psychiatric symptoms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 239000002117 illicit drug Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 238000000491 multivariate analysis Methods 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 208000019906 panic disease Diseases 0.000 description 3
- 208000022821 personality disease Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000011524 similarity measure Methods 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100021752 Corticoliberin Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000025307 bipolar depression Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229960002866 duloxetine Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000003064 k means clustering Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004452 microanalysis Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013179 statistical model Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000005011 time of flight secondary ion mass spectroscopy Methods 0.000 description 2
- 238000002042 time-of-flight secondary ion mass spectrometry Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 108700039964 Duplicate Genes Proteins 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000944267 Homo sapiens Inward rectifier potassium channel 4 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100033057 Inward rectifier potassium channel 4 Human genes 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 206010071368 Psychological trauma Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000012352 Spearman correlation analysis Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101150088517 TCTA gene Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101100398285 Xenopus laevis kit gene Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000013477 bayesian statistics method Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 101150110946 gatC gene Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012627 multivariate algorithm Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Medical Informatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Data Mining & Analysis (AREA)
- Evolutionary Biology (AREA)
- Databases & Information Systems (AREA)
- Software Systems (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Artificial Intelligence (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9227008P | 2008-08-27 | 2008-08-27 | |
| US61/092,270 | 2008-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20110057188A true KR20110057188A (ko) | 2011-05-31 |
Family
ID=41721907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117007024A Withdrawn KR20110057188A (ko) | 2008-08-27 | 2009-08-27 | 바이오마커 프로파일 측정 시스템 및 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110172501A1 (enExample) |
| EP (1) | EP2318551A4 (enExample) |
| JP (1) | JP2012501181A (enExample) |
| KR (1) | KR20110057188A (enExample) |
| CN (1) | CN102224256A (enExample) |
| AU (1) | AU2009285766A1 (enExample) |
| BR (1) | BRPI0914859A2 (enExample) |
| CA (1) | CA2728171A1 (enExample) |
| EA (1) | EA201071324A1 (enExample) |
| WO (1) | WO2010025216A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101483284B1 (ko) * | 2013-01-31 | 2015-01-15 | 한국과학기술원 | 질병 관련 단일염기다형성 조합 추출 방법, 질병 발생 위험도 예측 방법, 그리고 이를 이용한 질병 발생 위험도 예측 장치 |
| KR20200086627A (ko) * | 2017-11-13 | 2020-07-17 | 더 멀티플 마이얼로머 리서치 파운데이션, 인크. | 통합된, 분자, 체학, 면역요법, 대사, 후성적, 및 임상 데이터베이스 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8655807B2 (en) * | 2010-04-05 | 2014-02-18 | Applied Research Associates, Inc. | Methods for forming recognition algorithms for laser-induced breakdown spectroscopy |
| US8676739B2 (en) | 2010-11-11 | 2014-03-18 | International Business Machines Corporation | Determining a preferred node in a classification and regression tree for use in a predictive analysis |
| US9336302B1 (en) | 2012-07-20 | 2016-05-10 | Zuci Realty Llc | Insight and algorithmic clustering for automated synthesis |
| US20160209428A1 (en) * | 2013-08-21 | 2016-07-21 | The Regents Of The University Of California | Diagnostic and predictive metabolite patterns for disorders affecting the brain and nervous system |
| WO2022187670A1 (en) * | 2021-03-05 | 2022-09-09 | University Of North Texas Health Science Center At Fort Worth | Personalized medicine approach for treating cognitive loss |
| JP6364488B2 (ja) | 2013-11-26 | 2018-07-25 | ユニバーシティー オブ ノース テキサス ヘルス サイエンス センター アット フォートワースＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｔｅｘａｓ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅ Ｃｅｎｔｅｒ Ａｔ Ｆｏｒｔ Ｗｏｒｔｈ | 認知欠損を治療するための個別化医療的手法 |
| US9545227B2 (en) | 2013-12-13 | 2017-01-17 | Vital Connect, Inc. | Sleep apnea syndrome (SAS) screening using wearable devices |
| JP6882776B2 (ja) * | 2015-11-12 | 2021-06-02 | 国立大学法人九州大学 | うつ病診断用バイオマーカー及びその使用 |
| US11205103B2 (en) | 2016-12-09 | 2021-12-21 | The Research Foundation for the State University | Semisupervised autoencoder for sentiment analysis |
| US20190354814A1 (en) * | 2017-01-08 | 2019-11-21 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Systems and methods for using supervised learning to predict subject-specific bacteremia outcomes |
| CN110546277B (zh) | 2017-03-01 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| TWI640018B (zh) * | 2017-03-15 | 2018-11-01 | 長庚醫療財團法人林口長庚紀念醫院 | Data integration method |
| WO2019008987A1 (ja) * | 2017-07-07 | 2019-01-10 | パナソニックＩｐマネジメント株式会社 | 情報提供方法、情報処理システム、情報端末、及び情報処理方法 |
| CA3019970A1 (en) * | 2018-10-05 | 2020-04-05 | Fang Liu | Methods for diagnosing or treating post-traumatic stress disorder, and compositions therefor |
| US11537888B2 (en) * | 2019-05-15 | 2022-12-27 | The Florida International University Board Of Trustees | Systems and methods for predicting pain level |
| CN113210264B (zh) * | 2021-05-19 | 2023-09-05 | 江苏鑫源烟草薄片有限公司 | 烟草杂物剔除方法及装置 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190857B1 (en) * | 1997-03-24 | 2001-02-20 | Urocor, Inc. | Diagnosis of disease state using MRNA profiles in peripheral leukocytes |
| US5958688A (en) * | 1997-04-28 | 1999-09-28 | The Trustees Of The University Of Pennsylvania | Characterization of mRNA patterns in neurites and single cells for medical diagnosis and therapeutics |
| NO972006D0 (no) * | 1997-04-30 | 1997-04-30 | Forskningsparken I Aas As | Ny metode for diagnose av sykdommer |
| US20070178475A1 (en) * | 1998-09-17 | 2007-08-02 | Nehls Michael C | Novel human polynucleotides and polypeptides encoded thereby |
| WO2000040749A2 (en) * | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| DE10019058A1 (de) * | 2000-04-06 | 2001-12-20 | Epigenomics Ag | Detektion von Variationen des DNA-Methylierungsprofils |
| US7329489B2 (en) * | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| ES2305234T3 (es) * | 2001-02-27 | 2008-11-01 | Blanchette Rockefeller Neurosciences Institute | Diagnostico de la enfermedad de alzheimer basado en la fosforilacion de una proteina quinosa activada por mitogeno. |
| JP3771502B2 (ja) * | 2002-02-14 | 2006-04-26 | 国立大学法人 新潟大学 | 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法 |
| WO2004007762A2 (en) * | 2002-07-11 | 2004-01-22 | Novartis Ag | Genes associated with schizophrenia, adhd and bipolar disorders |
| JP2004135667A (ja) * | 2002-09-27 | 2004-05-13 | Japan Science & Technology Agency | 血液を用いた統合失調症の診断方法 |
| JP2004208547A (ja) * | 2002-12-27 | 2004-07-29 | Hitachi Ltd | うつ病の評価方法 |
| US20040248286A1 (en) * | 2003-03-21 | 2004-12-09 | Christine Konradi | Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof |
| WO2005020784A2 (en) * | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| WO2004111270A2 (en) * | 2003-06-13 | 2004-12-23 | The Babraham Institute | Differential gene expression in schizophrenia |
| US20050069936A1 (en) * | 2003-09-26 | 2005-03-31 | Cornelius Diamond | Diagnostic markers of depression treatment and methods of use thereof |
| US20050209181A1 (en) * | 2003-11-05 | 2005-09-22 | Huda Akil | Compositions and methods for diagnosing and treating mental disorders |
| US20050208519A1 (en) * | 2004-03-12 | 2005-09-22 | Genenews Inc. | Biomarkers for diagnosing schizophrenia and bipolar disorder |
| JP2005312435A (ja) * | 2004-03-29 | 2005-11-10 | Kazuhito Rokutan | うつ病の評価方法 |
| CN101133157A (zh) * | 2004-06-03 | 2008-02-27 | 阿什洛米克斯控股有限公司 | 诊断应激的药物和方法 |
| ES2660765T3 (es) * | 2004-06-21 | 2018-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor |
| US7736621B2 (en) * | 2004-08-03 | 2010-06-15 | Hypatia Ltd. | Methods for gauging the effect of a depression treatment by determining the levels of beta-arrestin 1 and G-protein coupled receptor kinase 2 |
| WO2006097244A2 (en) * | 2005-03-17 | 2006-09-21 | F. Hoffman-La Roche Ag | Methods for assessing emphysema |
| US20070122395A1 (en) * | 2005-10-06 | 2007-05-31 | Vanderbilt University | Genetic and pharmacological regulation of antidepressant-sensitive biogenic amine transporters through PKG/p38 map kinase |
| US7906281B2 (en) * | 2005-10-07 | 2011-03-15 | The Regents Of The University Of California | Method to predict the response to lithium treatment |
| WO2007044094A1 (en) * | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| US20080033598A1 (en) * | 2006-03-23 | 2008-02-07 | Hollingsworth Stephen A | Materials management system and method |
| US20070292880A1 (en) * | 2006-05-05 | 2007-12-20 | Robert Philibert | Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome |
| WO2007136797A1 (en) * | 2006-05-18 | 2007-11-29 | The Mclean Hospital Corporation | Methods for diagnosis and prognosis of psychotic disorders |
| WO2008011046A2 (en) * | 2006-07-17 | 2008-01-24 | The H.Lee Moffitt Cancer And Research Institute, Inc. | Computer systems and methods for selecting subjects for clinical trials |
| RU2473555C2 (ru) * | 2006-12-19 | 2013-01-27 | ДжинГоу, Инк. | Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных |
| WO2008124428A1 (en) * | 2007-04-03 | 2008-10-16 | Indiana University Research And Technology Corporation | Blood biomarkers for mood disorders |
| WO2008144371A1 (en) * | 2007-05-16 | 2008-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for diagnosing suicidal tendencies |
-
2009
- 2009-08-27 AU AU2009285766A patent/AU2009285766A1/en not_active Abandoned
- 2009-08-27 BR BRPI0914859A patent/BRPI0914859A2/pt not_active IP Right Cessation
- 2009-08-27 EP EP09810557A patent/EP2318551A4/en not_active Withdrawn
- 2009-08-27 EA EA201071324A patent/EA201071324A1/ru unknown
- 2009-08-27 US US13/000,405 patent/US20110172501A1/en not_active Abandoned
- 2009-08-27 WO PCT/US2009/055144 patent/WO2010025216A1/en not_active Ceased
- 2009-08-27 JP JP2011525187A patent/JP2012501181A/ja active Pending
- 2009-08-27 CA CA2728171A patent/CA2728171A1/en not_active Abandoned
- 2009-08-27 KR KR1020117007024A patent/KR20110057188A/ko not_active Withdrawn
- 2009-08-27 CN CN2009801428894A patent/CN102224256A/zh active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101483284B1 (ko) * | 2013-01-31 | 2015-01-15 | 한국과학기술원 | 질병 관련 단일염기다형성 조합 추출 방법, 질병 발생 위험도 예측 방법, 그리고 이를 이용한 질병 발생 위험도 예측 장치 |
| KR20200086627A (ko) * | 2017-11-13 | 2020-07-17 | 더 멀티플 마이얼로머 리서치 파운데이션, 인크. | 통합된, 분자, 체학, 면역요법, 대사, 후성적, 및 임상 데이터베이스 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012501181A (ja) | 2012-01-19 |
| AU2009285766A1 (en) | 2010-03-04 |
| EP2318551A4 (en) | 2012-10-24 |
| EA201071324A1 (ru) | 2011-12-30 |
| BRPI0914859A2 (pt) | 2015-11-03 |
| WO2010025216A1 (en) | 2010-03-04 |
| EP2318551A1 (en) | 2011-05-11 |
| WO2010025216A9 (en) | 2010-11-18 |
| CA2728171A1 (en) | 2010-03-04 |
| US20110172501A1 (en) | 2011-07-14 |
| CN102224256A (zh) | 2011-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20110057188A (ko) | 바이오마커 프로파일 측정 시스템 및 방법 | |
| CN109790583B (zh) | 对肺腺癌亚型分型的方法 | |
| RU2721916C2 (ru) | Способы прогнозирования рака предстательной железы | |
| AU2012381038B2 (en) | Interrogatory cell-based assays for identifying drug-induced toxicity markers | |
| DK2681333T3 (en) | EVALUATION OF RESPONSE TO GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASIS (GEP-NENE) THERAPY | |
| AU2014299322B2 (en) | Sepsis biomarkers and uses thereof | |
| CN101370946B (zh) | 用于使生物标志产物水平与疾病相关联的方法和装置 | |
| KR20140044341A (ko) | 암에 대한 분자적 진단 검사 | |
| KR20150090246A (ko) | 암을 위한 분자 진단 테스트 | |
| KR20140006898A (ko) | 결장암 유전자 발현 시그니처 및 이용 방법 | |
| KR20140140069A (ko) | 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법 | |
| KR20160117606A (ko) | 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험 | |
| CN111183233A (zh) | 使用靶基因表达的数学建模评估Notch细胞信号传导途径活性 | |
| KR20160052729A (ko) | 폐암에 대한 분자적 진단 검사 | |
| KR20100095564A (ko) | 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물 | |
| CN111479933A (zh) | 使用靶基因表达的数学建模评估jak-stat1/2细胞信号传导途径活性 | |
| CN111448325A (zh) | 使用靶基因表达的数学建模评估jak-stat3细胞信号传导途径活性 | |
| AU2015257483A1 (en) | Biomarkers and combinations thereof for diagnosising tuberculosis | |
| AU2016377391B2 (en) | Triage biomarkers and uses therefor | |
| KR20200081380A (ko) | 유전적 조절 | |
| KR20180088162A (ko) | 노화 진단용 조성물, 이를 포함하는 키트 및 이를 진단하는 방법 | |
| CN101111768A (zh) | 肺癌预后 | |
| KR102499713B1 (ko) | 췌장암을 앓는 환자의 생존 예후를 결정하는 방법 | |
| US20030175761A1 (en) | Identification of genes whose expression patterns distinguish benign lymphoid tissue and mantle cell, follicular, and small lymphocytic lymphoma | |
| WO2008081434A2 (en) | Methods and kits for diagnosis of multiple sclerosis in probable multiple sclerosis subjects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20110325 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |